A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.

Atul A DeodharAlan J KivitzMarina MagreyJessica A WalshPhilip J MeaseMaria GreenwaldFarid KianifardChelsea ElamGopi M BommidiAdam WinseckLianne S Gensler

Published in: Rheumatology (Oxford, England) (2024)

ClinicalTrials.gov, NCT03350815.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
clinical trial
study protocol
preterm birth